0001104659-20-032715.txt : 20200312
0001104659-20-032715.hdr.sgml : 20200312
20200312213906
ACCESSION NUMBER: 0001104659-20-032715
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200310
FILED AS OF DATE: 20200312
DATE AS OF CHANGE: 20200312
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Capponi Vincent
CENTRAL INDEX KEY: 0001368151
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36792
FILM NUMBER: 20710536
MAIL ADDRESS:
STREET 1: MEDASORB TECHNOLOGIES
STREET 2: 7 DEER PARK DRIVE, SUITE K
CITY: MONMOUTH JUNCTION
STATE: NJ
ZIP: 08852
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cytosorbents Corp
CENTRAL INDEX KEY: 0001175151
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 980373793
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7 DEER PARK DRIVE, SUITE K
CITY: MONMOUTH JUNCTION
STATE: NJ
ZIP: 08852
BUSINESS PHONE: 973-329-8885
MAIL ADDRESS:
STREET 1: 7 DEER PARK DRIVE, SUITE K
CITY: MONMOUTH JUNCTION
STATE: NJ
ZIP: 08852
FORMER COMPANY:
FORMER CONFORMED NAME: MedaSorb Technologies CORP
DATE OF NAME CHANGE: 20060807
FORMER COMPANY:
FORMER CONFORMED NAME: GILDER ENTERPRISES INC
DATE OF NAME CHANGE: 20020611
4
1
tm2011575d4_form4.xml
FORM 4
X0306
4
2020-03-10
0
0001175151
Cytosorbents Corp
CTSO
0001368151
Capponi Vincent
C/O CYTOSORBENTS CORPORATION
7 DEER PARK DRIVE, SUITE K
MONMOUTH JUNCTION
NJ
08852
0
1
0
0
Chief Operating Officer
Common Stock
2020-03-10
4
M
0
6500
3.45
A
417649
D
Common Stock
2020-03-10
4
M
0
4677
3.45
A
422326
D
Common Stock
2020-03-10
4
S
0
4677
6.00
D
417649
D
Stock Option (right to buy)
3.45
2020-03-10
4
M
0
6500
0
D
2020-05-05
Common Stock
6500
14800
D
Stock Option (right to buy)
3.45
2020-03-10
4
M
0
4677
0
D
2020-05-05
Common Stock
4677
10123
D
Stock option exercise conducted pursuant to a 10b5-1 trading plan adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
Open market sale conducted pursuant to a 10b5-1 trading plan adopted by the reporting person in accordance with Rule 10b5-1 of the Exchange Act.
Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, (c) 125,000 RSUs granted on April 8, 2015 and (d) 10,100 RSUs granted on March 15, 2018; and (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into common stock, par value $0.001 per share (the "Common Stock") of the Company upon vesting: (a) 36,067 RSUs granted on February 28, 2020 and unvested on the date hereof; (b) 36,067 RSUs granted on July 22, 2019 and unvested on the date hereof; (continued in footnote 4)
(continued from footnote 3) and (c) 1,540 RSUs granted on March 4, 2019 and unvested on the date hereof; and (iii) 136,975 shares of common stock owned by the reporting person.
These stock options were originally granted on May 5, 2010 and vested at the discretion of the Company's Board of Directors based on satisfying certain criteria including a timely completion of the sepsis trial, raising capital for the Company, and partnering and business development.
/s/ Kathleen P. Bloch attorney-in-fact for Vincent Capponi
2020-03-12